Bondlido FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 30, 2025.
FDA Approved: Yes (First approved September 25, 2025)
Brand name: Bondlido
Generic name: lidocaine
Dosage form: Topical System
Company: MEDRx Co., Ltd.
Treatment for: Postherpetic Neuralgia
Bondlido (lidocaine) is an amide local anesthetic topical system indicated in adults for relief of pain associated with post-herpetic neuralgia.
- Post-herpetic neuralgia (PHN) is the most common long-term complication of herpes zoster (shingles). It is characterized by a stabbing, burning pain that persists for three or more months after the onset of a herpes zoster outbreak.
- Bondlido contains lidocaine, a local anesthetic that reduces pain by blocking the transmission of pain signals at the ends of nerves. Lidocaine patches are widely used in the treatment of PHN.
- Bondlido is a new type of lidocaine patch that uses ILTS (Ionic Liquid Transdermal System), an exclusive MEDRx technology designed to increase the transdermal permeability of drugs.
- Bondlido patches are applied to the skin to cover the most painful area once for up to 12 hours in a 24-hour period.
- Warnings and precautions associated with Bondlido include accidental exposure to residual lidocaine, excessive dosing leading to serious adverse effects, higher blood concentrations of lidocaine from increased absorption due to application to non-intact skin, increased drug exposure due to external heat sources, methemoglobinemia, hypersensitivity reactions, and accidental eye exposure.
- Common adverse reactions are application site reactions such as irritation, erythema, and pruritus.
Development timeline for Bondlido
| Date | Article |
|---|---|
| Sep 25, 2025 | Approval FDA Approves Bondlido (lidocaine topical system) for the Treatment of Post-Herpetic Neuralgia |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.